参考文献: [1] Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3,open-label, multicentre, randomised trial. Lancet Oncol. 2012 Sep;13...
Strauss B.Best hope or last hope: access to phase III clinical trials of HER-2/neu for advanced stage breast cancer patients[J].J Adv Nurs, 2011,31 ( 2 ) : 259-266.Best hope or last hope: access to phase III clinical trials of HER-2/neu for advanced stage breast cancer patients....
Many years ago, a friend of a friend was diagnosed with stage 2 breast cancer. She suffered through many rounds of brutal surgeries, chemo and radiation treatments. She had some brief periods of remission, but the cancer always came back. Her toughness, positive attitude, and love for Jesus ...
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives Article 08 January 2024 Introduction About 20% of breast cancers are driven by amplification of the ERBB2 gene and overexpression of its gene product, the HER2 protein. A large body of...
Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003;21:...
[1] Prat A, Falato C, Brunet LP, et al. LBA3 - Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: final results of the SOLTI TOT-HER3 window of opportunity trial. Annals of Oncolog...
t always work and in some cases where it works, its effects only last a year or so. A new drugpertuzumabhas arrived which helps stop Herceptin being blocked in some cases. But the real question is - what’s a woman with stage 3 or 4 metastatic HER-2 positive breast cancer to do ...
HER-2 gene amplification and protein overexpression has been associated with increased risk of advanced-stage breast cancer and poor prognosis. Recently, a single missense point mutation (Ile(655)Val) in the transmembrane domain of the HER-2 gene was associated with a 40% increase in breast canc...
Among the RTK family members, Human epidermal growth factor receptor 2 (HER2) and HER3 are particularly relevant to breast cancer. The review delves into the complexities of receptor tyrosine kinase interactions, resistance mechanisms, and the potential of anti-HER3 drugs, offering valuable insights...
stage,to achieve surgical operation,maintain breast and armpit, and provide sensitive information of medicine in vivo.It plays an important role in the treatment of Her-2 negative breast cancer.In this paper, we will introduce the molecular classification of Her-2 negative breast cancer, the ...